The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
Open accessAbstract
Aims/hypothesis Obesity and insulin resistance are associated with low-grade chronic inflammation. Glucagon-like peptide-1 (GLP-1) is known to reduce insulin resistance. We investigated whether GLP-1 has anti-inflammatory effects on adipose tissue, including adipocytes and adipose tissue macrophages (ATM).Methods We administered a recombinant adenovirus (rAd) producing GLP-1 (rAd-GLP-1) to an ob/ob mouse model of diabetes. We examined insulin sensitivity, body fat mass, the infiltration of ATM and metabolic profiles. We analysed the mRNA expression of inflammatory cytokines, lipogenic genes, and M1 and M2 macrophage-specific genes in adipose tissue by real-time quantitative PCR. We also examined the activation of nuclear factor κB (NF-κB), extracellular signal-regulated kinase 1/2 and Jun N-terminal kinase (JNK) in vivo and in vitro.Results Fat mass, adipocyte size and mRNA expression of lipogenic genes were significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Macrophage populations (F4/80(+) and F4/80(+)CD11b(+)CD11c(+) cells), as well as the expression and production of IL-6, TNF-α and monocyte chemoattractant protein-1, were significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Expression of M1-specific mRNAs was significantly reduced, but that of M2-specific mRNAs was unchanged in rAd-GLP-1-treated ob/ob mice. NF-κB and JNK activation was significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Lipopolysaccharide-induced inflammation was reduced by the GLP-1 receptor agonist, exendin-4, in 3T3-L1 adipocytes and ATM.Conclusions/interpretation We suggest that GLP-1 reduces macrophage infiltration and directly inhibits inflammatory pathways in adipocytes and ATM, possibly contributing to the improvement of insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the adipose tissue of GLP-1-treated ob/ob mice expressing recombinant adenovirus, for instance, GLP-1RA has been shown to decrease the production of TNF-α, IL-6, and IL-1β, all of which are significant mediators of inflammation.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (27–32).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was reported that GLP-1 shows anti-inflammatory effects on pancreatic islets and adipose tissue, contributing to lowering glucose levels in diabetes [18–20].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Administration of a recombinant adenovirus producing GLP-1 (4 × 109 PFU/mouse) to ob/ob mice reduced the macrophage population and production of TNF-α, MCP-1, and IL-6 in adipose tissue via inhibition of nuclear factor-kappa B (NF-κB) activation and phosphorylation of ERK1/2 and c-Jun N-terminal kinases [18].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 receptor agonists may potentially reduce inflammation and oxidative stress in adipose tissue by affecting the expression of cytokines, chemokines, and macrophage infiltration, with prolonged GLP-1 action potentially alleviating obesity-related adipose tissue inflammation while enhancing the expression of anti-inflammatory genes [17,18]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [17]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Similar antiinflammatory effects of GLP-1 have been reported in human macrophage cell lines (66), and systemic effects of GLP-1 agonists on macrophage infiltration have been previously reported (67).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [67]
In the citing paper
“Treatment of Huh7 and HepG2 hepatoma cells with exenatide decreased intracellular lipid accumulation [181,182] by enhancing fatty acid oxidation and reducing lipogenesis [160,161,179,183].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [182]
In the citing paper
“Treatment with GLP-1 RAs is also able to reduce macrophage infiltration of adipose tissue and inhibit inflammatory pathways in adipocytes, concurring to ameliorate insulin sensitivity [138].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [138]
In the citing paper
“In fact, new research suggests that GLP-1 RAs may reduce the production of pro-inflammatory cytokines and immune cell infiltration to reduce inflammation in many tissues, including AT [73].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [73]
In the citing paper
“Furthermore, GLP-1 RAs prevent resident macrophages in AT from being activated by nuclear factor-kappa B (NF-κB) [73].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [73]
In the citing paper
“Studies have shown that GLP-1 and its analogs have anti-inflammatory properties.”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard, J., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H., Capeau, J., & Fève, B. (2006) · PubMed · Cited by 2,090
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase
Nidai Ozes, O., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999) · Nature · doi:10.1038/43466 · Cited by 1,832
IKK-β links inflammation to obesity-induced insulin resistance
Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z.-W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., & Karin, M. (2005) · Nature Medicine · doi:10.1038/nm1185 · Cited by 1,773
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,425
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Cited by
Sorted by citations
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
Self-citationThe anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Obesity and cancer: existing and new hypotheses for a causal connection
Stone, T. W., McPherson, M., & Gail Darlington, L. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.02.022 · Cited by 262
Wei, Y., Zhang, J. (., Li, Z., Gow, A., Chung, K. F., Hu, M., Sun, Z., Zeng, L., Zhu, T., Jia, G., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500142 · Cited by 246
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
Hogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal‐Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 235
Bleau, C., Karelis, A. D., St‐Pierre, D. H., & Lamontagne, L. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2617 · Cited by 222
Impact of Gut Microbiota on Host Glycemic Control
Gérard, C., & Vidal, H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00029 · Cited by 220
Inflammation and resolution in obesity
Soták, M., Clark, M., Suur, B. E., & Börgeson, E. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01047-y · Cited by 260
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
Solerte, S. B., Sabatino, A. D., Galli, M., & Fiorina, P. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01539-z · Cited by 197
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.055 · Cited by 213
Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats
Zhang, Q., Yu, H., Xiao, X., Hu, L., Xin, F., & Yu, X. (2018) · PeerJ · doi:10.7717/peerj.4446 · Cited by 188
Metaflammation in obesity and its therapeutic targeting
Schleh, M. W., Caslin, H. L., Garcia, J. N., Mashayekhi, M., Srivastava, G., Bradley, A. B., & Hasty, A. H. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf9382 · Cited by 197
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 178
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Han, Y., Li, Y., & He, B. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.04.017 · Cited by 159
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-05323-7 · Cited by 160
Liu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13454 · Cited by 155
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Teodoro, J. S., Nunes, S., Rolo, A. P., Reis, F., & Palmeira, C. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01857 · Cited by 150
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Inflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
Hypoglycemic agents and potential anti-inflammatory activity
Mathews, S. T., Kothari, V. M., & Galdo, J. A. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s86917 · Cited by 133
Barbieri, M., Rizzo, M. R., Marfella, R., Boccardi, V., Esposito, A., Pansini, A., & Paolisso, G. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.018 · Cited by 127
Bizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123
Badawi, G. A., Fattah, M. A. A. E., Zaki, H. F., & Sayed, M. I. E. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0331-6 · Cited by 125
Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
Konwerski, M., Gąsecka, A., Opolski, G., Grabowski, M., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11030355 · Cited by 130
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
Nedosugova, L. V., Markina, Y. V., Бочкарева, Л. А., Кузина, И. А., Petunina, N. A., Yudina, I. Y., & Kirichenko, T. V. (2022) · Biomedicines · doi:10.3390/biomedicines10051168 · Cited by 135
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Mechanism of action of the bile acid receptor TGR5 in obesity
Lun, W., Yan, Q., Guo, X., Zhou, M., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.011 · Cited by 122
Guo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., & Gu, X. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165826 · Cited by 112
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Self-citationWang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Park, B., Bakbak, E., Teoh, H., Krishnaraj, A., Dennis, F., Quan, A., Rotstein, O. D., Butler, J., Hess, D. A., & Verma, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00574.2023 · Cited by 119
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 109
Onal, E. M., Afşar, B., Covic, A. C., Vaziri, N. D., & Kanbay, M. (2018) · Hypertension Research · doi:10.1038/s41440-018-0144-z · Cited by 108
Monji, A., Mitsui, T., Bando, Y., Aoyama, M., Shigeta, T., & Murohara, T. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00990.2012 · Cited by 108
Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.043 · Cited by 106
Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.03.004 · Cited by 100
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“…GLP-1R expression in peripheral tissues is generally low and restricted to rare cell types (26), antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (27–32).”
Tate, M., Robinson, E., Green, B. D., McDermott, B. J., & Grieve, D. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-015-0518-1 · Cited by 96
Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
Iturbe-Rey, S., Maccali, C., Arrese, M. A., Aspichueta, P., de Oliveira, C. P. M. S., Castro, R. E., Lapitz, A., Izquierdo‐Sánchez, L., Bujanda, L., Perugorria, M. J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119053 · Cited by 102
Ni, Y., Ni, L., Zhuge, F., Xu, L., Fu, Z., & Ota, T. (2020) · Obesity · doi:10.1002/oby.22674 · Cited by 92
GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress
Jiang, Y., Wang, Z., Ma, B., Fan, L., Yi, N., Lu, B., Wang, Q., & Liu, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01168 · Cited by 88
Liu, J., Yang, K., Yang, J., Xiao, W., Le, Y., Yu, F., Gu, L., Lang, S., Tian, Q., Jin, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.037 · Cited by 85
Human Postprandial Nutrient Metabolism and Low-Grade Inflammation: A Narrative Review
Meessen, E. C. E., Warmbrunn, M. V., Nieuwdorp, M., & Soeters, M. R. (2019) · Nutrients · doi:10.3390/nu11123000 · Cited by 95
Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes
YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84
Jouy, S. H., Mohan, S., Scichilone, G., Mostafa, A., & Mahmoud, A. M. (2024) · Biomedicines · doi:10.3390/biomedicines12092129 · Cited by 96
Impact of hyperglycemia on immune cell function: a comprehensive review
Lee, H., Kim, M.-J., Lee, I.-K., Hong, C.-W., & Jeon, J. (2024) · Diabetology International · doi:10.1007/s13340-024-00741-6 · Cited by 95
Bułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., & Okopień, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.008 · Cited by 79
Macrophage Responses to Environmental Stimuli During Homeostasis and Disease
Rasheed, A., & Rayner, K. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab004 · Cited by 83
Kawakubo, M., Tanaka, M., Ochi, K., Watanabe, A., Saka-Tanaka, M., Kanamori, Y., Yoshioka, N., Yamashita, S., Goto, M., Itoh, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57935-6 · Cited by 74
Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 72
Macrophages and T cells in metabolic disorder-associated cancers
Taranto, D., Kloosterman, D. J., & Akkari, L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00743-1 · Cited by 81
Gao, H., Zeng, Z., Zhang, H., Zhou, X., Guan, L., Deng, W., & Xu, L. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00505 · Cited by 74
Bifari, F., Manfrini, R., Dei, M., Berra, C., Siano, M., Zuin, M. G., Paroni, R. C., & Folli, F. B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 71
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Immune Modulation of Brown(ing) Adipose Tissue in Obesity
van den Berg, S. M., van Dam, A. D., Rensen, P. C. N., de Winther, M. P. J., & Lutgens, E. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1066 · Cited by 69
GOU, S., ZHU, T., WANG, W., XIAO, M., WANG, X.-C., & CHEN, Z.-H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.010 · Cited by 66
Kihira, Y., Miyake, M., Hirata, M., Hoshina, Y., Kato, K., Shirakawa, H., Sakaue, H., Yamano, N., Izawa‐Ishizawa, Y., Ishizawa, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093856 · Cited by 69
Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117152 · Cited by 68
GLP-1: A Mediator of the Beneficial Metabolic Effects of Bariatric Surgery?
Manning, S., Pucci, A. B. F., & Batterham, R. L. (2015) · Physiology · doi:10.1152/physiol.00027.2014 · Cited by 65
Rafeh, R. W., Viveiros, A., Oudit, G. Y., & EL‐Yazbi, A. F. (2020) · Clinical Science · doi:10.1042/cs20190227 · Cited by 63
Shinjo, T., Nakatsu, Y., Iwashita, M., Sano, T., Sakoda, H., Ishihara, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Tsuchiya, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00553.2014 · Cited by 59
Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice
Xu, Q., Zhang, X., Li, T., & Shao, S. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00574-6 · Cited by 61
Regulatory mechanisms of macrophage polarization in adipose tissue
Pan, D., Guo, L., Jiang, C., Hu, J., & Hu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1149366 · Cited by 64
Hyperlipidemia-Induced MicroRNA-155-5p Improves β-Cell Function by TargetingMafb
Zhu, M., Wei, Y., Geißler, C., Abschlag, K., Corbalán-Campos, J., Hristov, M., Möllmann, J., Lehrke, M., Karshovska, E., & Schober, A. (2017) · Diabetes · doi:10.2337/db17-0313 · Cited by 58
Jinnouchi, H., Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Suzuki, T., MIYAMOTO, F., Kajiwara, K., Matsui, K., & Jinnouchi, T. (2015) · Journal of Diabetes Research · doi:10.1155/2015/706416 · Cited by 59
Wan, S., & Sun, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7347 · Cited by 55
Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., & Demizieux, L. (2021) · Diabetes Care · doi:10.2337/dc20-1843 · Cited by 54
Renoprotective Effects of DPP-4 Inhibitors
Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., & Tanabe, M. (2021) · Antioxidants · doi:10.3390/antiox10020246 · Cited by 63
Ejarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53
Bonfioli, G. B., Rodella, L., Metra, M., & Vizzardi, E. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10450-6 · Cited by 58
Shi, F.-H., Li, H., Cui, M., Zhang, Z.-L., Gu, Z.-C., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00576 · Cited by 50
DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis
Yang, Y., Cai, Z., & Zhang, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251916 · Cited by 49
Role of Incretin Axis in Inflammatory Bowel Disease
Duan, L., Rao, X., Braunstein, Z., Toomey, A. C., & Zhong, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01734 · Cited by 50
Targher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 52
Gaspari, T. A., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 52
GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction
Pastel, E., McCulloch, L. J., Ward, R., Joshi, S., Gooding, K. M., Shore, A. C., & Kos, K. (2017) · Clinical Science · doi:10.1042/cs20160803 · Cited by 49
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48
Chiou, H.-Y. C., Lin, M., Hsiao, P., Chen, C., Chiao, S., Lin, T.-Y., Chen, Y., Wu, D.-C., & Lin, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071584 · Cited by 52
Simental‐Mendía, L. E., Sánchez‐García, A., Linden‐Torres, E., & Simental-Mendía, M. A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108899 · Cited by 51
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 50
Anti‐inflammatory effects of linagliptin in hemodialysis patients with diabetes
Nakamura, Y., Tsuji, M., Hasegawa, H., Kimura, K., Fujita, K., Inoue, M., Shimizu, T., Gotoh, H., Goto, Y., Inagaki, M., et al. (2014) · Hemodialysis International · doi:10.1111/hdi.12127 · Cited by 46
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
Tsai, W.-H., Sung, F., Chiu, L., Shih, Y., Tsai, M.-C., & Wu, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.765446 · Cited by 49
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 53
Metabolic dysfunction and early‐onset colorectal cancer – how macrophages build the bridge
Scheurlen, K. M., Billeter, A. T., O'Brien, S. J., & Galandiuk, S. (2020) · Cancer Medicine · doi:10.1002/cam4.3315 · Cited by 44
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“…and oxidative stress in adipose tissue by a ff ecting the expression of cytokines, chemokines, and macrophage in-fi ltration, with prolonged GLP-1 action potentially alleviating obesity-related adipose tissue in fl ammation while enhancing the expression of anti-in fl ammatory genes [17,18] (Figure”
BackgroundDulaglutide mitigates inflammatory response in fibroblast-like synoviocytes
Zheng, W., Pan, H., Wei, L., Gao, F., & Lin, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.034 · Cited by 43
Qi, L., Gröger, M., Sharma, A., Goswami, I., Chen, E., Zhong, F., Ram, A., Healy, K. E., Hsiao, E. C., Willenbring, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52258-w · Cited by 49
Huang, J., Yi, H., Zhao, C., Zhang, Y., Zhū, L., Liu, B., He, P., & Zhou, M. (2018) · International Journal of COPD · doi:10.2147/copd.s175145 · Cited by 45
Metadata
- Authors
- Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Gachon University Gil Medical Center (KR)
- Ajou University (KR)
- Seoul National University (KR)
- Corresponding author
- Jun, H.-S.
- Venue
- Diabetologia
- Published
- 2012-06-22
- Volume
- 55
- Issue
- 9
- Pages
- 2456-2468
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1993624198
- Cited by
- 319
- References
- 47
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 35 · 2023: 29 · 2022: 25 · 2021: 24 · 2020: 17 · 2019: 26 · 2018: 17 · 2017: 15 · 2016: 17 · 2015: 17 · 2014: 18 · 2013: 12 · 2012: 2
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- AJOU Open Repository (Ajou University) (submittedVersion)
- Funders
- National Research Foundation
- National Research Foundation of Korea (A062260)
- Korea Science and Engineering Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, adipose tissue macrophages, adipose tissue inflammation, obesity, type 2 diabetes, insulin resistance, ob/ob mice, adipocyte size, lipogenic gene expression, macrophage polarization, NF-κB, JNK, exendin-4, lipopolysaccharide-induced inflammation, adipocyte inflammation, adipose tissue mass
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adipose Tissue, Animals, Anti-Inflammatory Agents, Gene Expression Regulation, Inflammation, Insulin Resistance, Macrophages, Mice, Obese, Obesity, NF-kappa B, Receptors, Glucagon, Body Fat Distribution, Mice, Glucagon-Like Peptide 1, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
